Janus Henderson Group PLC increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 10.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,711,459 shares of the company's stock after purchasing an additional 161,962 shares during the quarter. Janus Henderson Group PLC owned approximately 4.57% of Entrada Therapeutics worth $27,358,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. US Bancorp DE purchased a new position in Entrada Therapeutics during the third quarter worth about $42,000. SG Americas Securities LLC purchased a new position in shares of Entrada Therapeutics during the 3rd quarter worth about $156,000. Acadian Asset Management LLC increased its position in Entrada Therapeutics by 135.1% during the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company's stock worth $190,000 after purchasing an additional 7,682 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Entrada Therapeutics by 34.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company's stock worth $226,000 after purchasing an additional 3,644 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Entrada Therapeutics by 87.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company's stock valued at $394,000 after purchasing an additional 12,868 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.
Analyst Upgrades and Downgrades
TRDA has been the subject of a number of research analyst reports. Oppenheimer upped their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an "outperform" rating in a report on Wednesday, November 6th. Roth Capital upgraded Entrada Therapeutics to a "strong-buy" rating in a research note on Thursday. HC Wainwright raised their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Finally, Roth Mkm initiated coverage on Entrada Therapeutics in a report on Thursday. They set a "buy" rating and a $29.00 target price for the company.
Check Out Our Latest Research Report on TRDA
Insiders Place Their Bets
In other news, CFO Kory James Wentworth sold 3,195 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $14.97, for a total value of $47,829.15. Following the completion of the transaction, the chief financial officer now directly owns 76,486 shares in the company, valued at approximately $1,144,995.42. This represents a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total transaction of $54,108.00. Following the sale, the insider now directly owns 160,888 shares in the company, valued at $3,224,195.52. This trade represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,934 shares of company stock worth $515,582 over the last quarter. 7.59% of the stock is owned by corporate insiders.
Entrada Therapeutics Stock Performance
Shares of NASDAQ:TRDA traded up $1.27 during midday trading on Friday, hitting $21.59. 81,524 shares of the company's stock traded hands, compared to its average volume of 135,822. The firm's fifty day moving average price is $18.09 and its two-hundred day moving average price is $16.47. Entrada Therapeutics, Inc. has a twelve month low of $11.35 and a twelve month high of $21.63. The company has a market cap of $807.90 million, a PE ratio of 13.58 and a beta of -0.18.
Entrada Therapeutics Company Profile
(
Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
